PT-141 (Bremelanotide): The Melanocortin Sexual-Response Peptide
PT-141 — bremelanotide — is an approved melanocortin-receptor agonist with a defined indication (hypoactive sexual desire disorder in premenopausal women) and a specific side-effect profile. It is one of the few research-discussed peptides with regulatory approval.
primary CNS receptor target underlying the sexual-response effect.
approved as Vyleesi for HSDD in premenopausal women in the US.
administered subcutaneously approximately 45 minutes before anticipated sexual activity.
nausea is the most common adverse event in pivotal trials.
Bremelanotide is a synthetic cyclic heptapeptide agonist at melanocortin receptors (primarily MC3 and MC4) that acts on CNS sexual-response pathways. It is FDA-approved (Vyleesi, 2019) for hypoactive sexual desire disorder in premenopausal women. Efficacy in pivotal trials is modest but statistically significant; side effects include nausea and transient blood-pressure elevation. EU and UK regulatory status differs and should be checked locally.
An approved peptide medicine for a defined indication. Marketing claims about general 'libido enhancement' across populations stretch beyond the trial evidence.
What it is
PT-141 is bremelanotide — a synthetic cyclic heptapeptide derived from melanotan II's parent peptide, alpha-MSH. The molecule was developed specifically as a sexual-response agent after the parent compound's effects in early melanotan trials were observed.
Mechanistically it is an agonist at multiple melanocortin receptors, with MC4 considered the primary CNS target for the sexual-response effect. The mechanism is central, not vascular — unlike PDE5 inhibitors.
It is administered subcutaneously approximately 45 minutes before anticipated sexual activity. It is not a daily medication.
Pharmacology summary
| Layer | What the research describes |
|---|---|
| Receptor | Agonist at MC1, MC3, MC4 (and weaker MC5); MC4 thought central to sexual-response effect. |
| CNS action | Acts on hypothalamic pathways implicated in sexual motivation and arousal. |
| Onset | Approximately 45 minutes; peak effects within 1–3 hours. |
| Route | Subcutaneous autoinjector (Vyleesi formulation). |
| Not vascular | Unlike PDE5 inhibitors, mechanism is central rather than peripheral haemodynamic. |
Central rather than peripheral mechanism is the meaningful distinction from sildenafil-class drugs.
Clinical evidence and side effects
Pivotal trials
Two phase 3 trials in premenopausal women with HSDD; statistically significant improvements in desire and distress scores vs placebo, with modest effect sizes.
Common side effects
Nausea (most common), flushing, headache, injection-site reactions. Transient small blood-pressure elevations.
Contraindications
Uncontrolled hypertension or established cardiovascular disease per label; melanocortin-mediated effects on melanocytes can produce focal hyperpigmentation with repeat dosing.
The trial data justify the indication but not the broader marketing narrative. Effect sizes are modest; the population studied is narrow; off-label use in men or postmenopausal women is not supported by the registration data.
Side effects are real and predictable from melanocortin pharmacology: nausea, transient blood-pressure changes, and pigmentation effects with repeat dosing. The risk-benefit calculation in any individual case belongs in clinic.
What we know, what's still open
- FDA approval (HSDD): Established 2019 (Vyleesi) for premenopausal women.
- Effect size: Modest, statistically significant in pivotal trials.
- Mechanism: Well-characterised central melanocortin pharmacology.
- Off-label populations: Not supported by registration data.
- Long-term outcomes: Pharmacovigilance ongoing; long-term cardiovascular and pigmentation data evolving.
Frequently asked
Does it work in men?
Not approved in men. Some earlier trials investigated male sexual dysfunction; the approved indication is HSDD in premenopausal women.
How is it different from sildenafil?
Mechanism is central (MC4 in hypothalamic pathways) rather than peripheral haemodynamic. Different drug class entirely.
Is it safe long-term?
Approved with ongoing pharmacovigilance. Pigmentation effects and small blood-pressure elevations are documented; long-term cardiovascular outcomes still accumulating.
Is it the same as PT-141 sold as research?
Chemically the same molecule. The approved product (Vyleesi) is a manufactured pharmaceutical with defined formulation; research material is not appropriate for clinical use.
Where to read further
- • Kingsberg SA et al. Bremelanotide for HSDD — RECONNECT trials. Obstet Gynecol 2019.
- • Vyleesi US Prescribing Information.
- • Molinoff PB et al. PT-141 melanocortin pharmacology — early development literature.